Evidence map›Paper›PMID 29032396›Full record

Observational studyCardiovascular drugs and therapy2017

Assessing Adherence to Antihypertensive Therapy in Primary Health Care in Namibia: Findings and Implications.

M M Nashilongo, B Singu, F Kalemeera, M Mubita, E Naikaku, A Baker, A Ferrario, B Godman, L Achieng, D Kibuule

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in Cardiovascular drugs and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Arabic translation and cultural adaptation of Hill-Bone compliance to high blood pressure therapy scale.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

M M NashilongoSchool of Pharmacy, Faculty of Health Sciences, University of Namibia, Box 13301, 340 Mandume Ndemufayo Avenue Pioneers Park, Windhoek, Namibia.
B SinguSchool of Pharmacy, Faculty of Health Sciences, University of Namibia, Box 13301, 340 Mandume Ndemufayo Avenue Pioneers Park, Windhoek, Namibia.
F KalemeeraSchool of Pharmacy, Faculty of Health Sciences, University of Namibia, Box 13301, 340 Mandume Ndemufayo Avenue Pioneers Park, Windhoek, Namibia.
M MubitaSchool of Pharmacy, Faculty of Health Sciences, University of Namibia, Box 13301, 340 Mandume Ndemufayo Avenue Pioneers Park, Windhoek, Namibia.
E NaikakuSchool of Pharmacy, Faculty of Health Sciences, University of Namibia, Box 13301, 340 Mandume Ndemufayo Avenue Pioneers Park, Windhoek, Namibia.
A BakerStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
A FerrarioLSE Health, London School of Economics and Political Science, London, UK.
B GodmanStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK. brian.godman@strath.co.uk.
L AchiengDepartment of Medicine, University of Nairobi, Nairobi, Kenya.
D KibuuleSchool of Pharmacy, Faculty of Health Sciences, University of Namibia, Box 13301, 340 Mandume Ndemufayo Avenue Pioneers Park, Windhoek, Namibia.
University of Namibia · NAUniversity of Strathclyde · GBLondon School of Economics and Political Science · GBUniversity of Nairobi · KE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNamibia has the highest burden and incidence of hypertension in sub-Sahara Africa. Though non-adherence to antihypertensive therapy is an important cardiovascular risk factor, little is known about potential ways to improve adherence in Namibia following universal access. The objective of this study is to validate the Hill-Bone compliance scale and determine the level and predictors of adherence to antihypertensive treatment in primary health care settings in sub-urban townships of Windhoek, Namibia.

methodsReliability was determined by Cronbach's alpha. Principal component analysis (PCA) was used to assess construct validity.

resultsThe PCA was consistent with the three constructs for 12 items, explaining 24.1, 16.7 and 10.8% of the variance. Cronbach's alpha was 0.695. None of the 120 patients had perfect adherence to antihypertensive therapy, and less than half had acceptable levels of adherence (≥ 80%). The mean adherence level was 76.7 ± 8.1%. Three quarters of patients ever missed their scheduled clinic appointment. Having a family support system (OR = 5.4, 95% CI 1.687-27.6, p = 0.045) and attendance of follow-up visits (OR = 3.1, 95% CI 1.1-8.7, p = 0.03) were significant predictors of adherence. Having HIV/AIDs did not lower adherence.

conclusionsThe modified Namibian version of the Hill-Bone scale is reliable and valid for assessing adherence to antihypertensives in Namibia. There is sub-optimal adherence to antihypertensive therapy among primary health cares in Namibia. This needs standardized systems to strengthen adherence monitoring as well as investigation of other factors including transport to take full advantage of universal access.

Indexed as

Drug MonitoringAntihypertensive AgentsCross-Sectional StudiesHumansHypertensionNamibiaPrimary Health CarePrincipal Component AnalysisAntihypertensive AgentsAdherenceHypertensionNamibiaPrimary health careUniversal access

Identifiers

PMID29032396
PMCPMC5730630
OpenAlexW2743658562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.